ANLBIO, a biotechnology company developing gene therapies for neurodegenerative diseases, has selected Biovian Oy as a CDMO partner. The agreement covers process development for ANLBIO’s proprietary gene therapy vector, ANL-101, followed by 200 L scale …
A conversation with Pirjo Merilahti, PhD., Virology. At Biovian, Viral Vector process development is planned and executed by a team of experienced scientists, led by Dr Pirjo Merilahti. Her team typically starts the project with …
